Faron Presents Updated BEXMAB Data at ASH 2025: Deep and Durable Responses in HR-MDS with Favorable Safety Profile

About this update from Faron Pharmaceuticals Oy

[{"type":"text","content":"TURKU, FI / ACCESS Newswire / December 8, 2025 / Faron Pharmaceuticals (HEL:FARON)(LSE:FARN) - Significant efficacy observed in TP53-mutated patients with a 70% complete remission rate in the frontline HR MDS","length":208,"tagName":"p"},{"type":"text","content":"Key highlights:","length":15,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Median overall survival (mOS) with bexmarilimab and azacitidine in relapsed/refractory (r/r) HR-MDS patients reached 14.5 months (increased from 13.4 months observed earlier), a significant improvement in a population with historically poor survival of only 5-6 months","length":268,"tagName":"p"}]},{"val":[{"type":"text","content":"In treatment-naïve patients with HR-MDS and TP53 mutation, the combination achieved a remarkable 70% complete remission (CR) rate","length":129,"tagName":"p"}]},{"val":[{"type":"text","content":"Deep responses allowed 50% of treatment-naïve TP53-mutated patients and 21% of r/r TP53-mutated patients to proceed to stem cell transplant (SCT)","length":145,"tagName":"p"}]},{"val":[{"type":"text","content":"For the first time, data shows 57% of frontline patients who were transfusion-dependent at baseline achieved transfusion independence, confirming restoration of healthy bone marrow function","length":189,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":731,"olType":false},{"type":"text","content":"TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM:FARN, First North:FARON), a clinical-stage biopharmaceutical company, today announced updated full data from its Phase 1/2 BEXMAB study, presented at the American Society of Hematology (ASH) 2025 Annual Meeting (oral and poster presentation). The data highlights significant improvement in survival outcome and new findings on hematopoietic recovery in patients with higher-risk Myelodysplastic Syndromes (HR-MDS) treated with bexmarilimab in combination with standard-of-care azacitidine.","length":538,"tagName":"p"},{"type":"text","content":"Deep and durable response across HR-MDS subgroups","length":49,"tagName":"p"},{"type":"text","content":"The BEXMAB study continues to show deep and durable responses across HR-MDS subgroups, particularly in patients with TP53 mutations, a genetic profile typically associated with resistance to standard therapies.","length":210,"tagName":"p"},{"type":"text"...

More updates from Faron Pharmaceuticals Oy